

Danny Rischin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4008374/publications.pdf>

Version: 2024-02-01

174
papers

16,874
citations

34105
52
h-index

15266
126
g-index

174
all docs

174
docs citations

174
times ranked

15707
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors. <i>Australasian Journal of Dermatology</i> , 2022, 63, 43-52.	0.7	3
2	A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy. <i>Supportive Care in Cancer</i> , 2022, 30, 4243-4253.	2.2	6
3	Survival with Cemiplimab in Recurrent Cervical Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 544-555.	27.0	182
4	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	1.5	17
5	A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. <i>Investigational New Drugs</i> , 2022, 40, 782-788.	2.6	5
6	Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 834068.	2.8	15
7	Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
8	Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. <i>Annals of Oncology</i> , 2022, 33, 804-813.	1.2	5
9	C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9592-TPS9592.	1.6	0
10	Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5531-5531.	1.6	0
11	Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13531.	1.7	4
12	Sexual Health and Interpersonal Relationships After Chemoradiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A Cross-sectional Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 382-393.	0.8	10
13	Locoregional Radiation Therapy for De Novo Metastatic Nasopharyngeal Cancer: One Size Fits All?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 131-133.	0.8	1
14	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 613-620.	2.3	0
15	Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. <i>Advances in Therapy</i> , 2021, 38, 2365-2378.	2.9	7
16	Contralateral neck failure in oral tongue cancer: Outcomes from two centers using predefined treatment criteria. <i>Head and Neck</i> , 2021, 43, 2024-2031.	2.0	4
17	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 656611.	2.8	4
18	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1508-e1513.	3.7	16

#	ARTICLE	IF	CITATIONS
19	Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.. Journal of Clinical Oncology, 2021, 39, 6036-6036.	1.6	4
20	Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol. BMC Health Services Research, 2021, 21, 513.	2.2	5
21	Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.. Journal of Clinical Oncology, 2021, 39, 109-109.	1.6	1
22	Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) â€” A Trans-Tasman Radiation Oncology Group Study. International Journal of Radiation Oncology Biology Physics, 2021, 111, 876-886.	0.8	68
23	Fear of Cancer Recurrence in Survivors of Human Papillomavirusâ€”Associated Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 111, 890-899.	0.8	12
24	Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer â€” A review of the literature and PRO methodology. Oral Oncology, 2021, 118, 105309.	1.5	10
25	Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. , 2021, 9, e002757.		46
26	FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. Cancer Imaging, 2021, 21, 57.	2.8	11
27	Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort. Oral Oncology, 2021, 122, 105560.	1.5	3
28	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. Cancers, 2021, 13, 5645.	3.7	6
29	Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer. Journal of Clinical Oncology, 2021, , JCO2102364.	1.6	1
30	Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 796197.	2.8	11
31	Radiation oncology outpatient medication management needs and service gaps â€” A cross-sectional study of patients and clinicians. Journal of Oncology Pharmacy Practice, 2020, 26, 846-852.	0.9	3
32	Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. Oral Oncology, 2020, 101, 104516.	1.5	17
33	Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial â€” A Trans-Tasman Radiation Oncology Group study. Oral Oncology, 2020, 110, 104988.	1.5	4
34	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research, 2020, 26, 5153-5161.	7.0	58
35	Surgical management of recurrent cutaneous squamous cell carcinoma of the head and neck after definitive surgery and radiotherapy. ANZ Journal of Surgery, 2020, 90, 1391-1395.	0.7	2
36	Impact of histological Oral Tongue Cancer margins on locoregional recurrence: A multi-centre retrospective analysis. Oral Oncology, 2020, 111, 105004.	1.5	10

#	ARTICLE	IF	CITATIONS
37	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 322-328.	1.4	51
38	Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors. <i>Frontiers in Oncology</i> , 2020, 10, 930.	2.8	31
39	Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. <i>Lancet Oncology</i> , The, 2020, 21, e350-e359.	10.7	96
40	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	2.4	36
41	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. <i>Journal of Clinical Oncology</i> , 2020, 38, 2552-2557.	1.6	58
42	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
43	Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 85-90.	1.7	10
44	Outcomes of curative (chemo)radiotherapy for patients with non-p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 271-278.	1.8	1
45	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2020, 21, 294-305.	10.7	304
46	Carboplatin dosing in the era of IDMS-creatinine; the Cockcroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. <i>Gynecologic Oncology</i> , 2020, 157, 793-798.	1.4	8
47	Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. <i>Supportive Care in Cancer</i> , 2020, 28, 6023-6034.	2.2	7
48	Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10018-10018.	1.6	34
49	A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10084-TPS10084.	1.6	5
50	Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s124.	0.3	1
51	A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 130-139.	0.9	16
52	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	13.7	1,804
53	Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 97-105.	2.3	3
54	Unilateral radiotherapy treatment for p16/human papillomavirus-“positive squamous cell carcinoma of unknown primary in the head and neck. <i>Laryngoscope</i> , 2018, 128, 2076-2083.	2.0	11

#	ARTICLE	IF	CITATIONS
55	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018, 52, 228-240.	9.6	314
56	Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 295-304.	3.4	93
57	The role of human papillomavirus in p16-positive oral cancers. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 18-24.	2.7	29
58	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3152-3161.	1.6	153
59	High-Dose Cisplatin for Head and Neck Cancer Lives On. <i>Journal of Clinical Oncology</i> , 2018, 36, 1055-1057.	1.6	5
60	Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1275-1283.	1.6	134
61	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
62	A clinical trial with protracted infusion 5-fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 15, 75-81.	1.1	0
63	Non-smoking, non-drinking elderly females, a 5-year follow-up of a clinically distinct cohort of oral squamous cell carcinoma patients. <i>Oral Oncology</i> , 2018, 86, 113-120.	1.5	31
64	Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCMC system in a quaternary oncology centre. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 865-876.	2.3	8
65	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	27.0	997
66	The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 397-438.	0.2	0
67	Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 678-686.	0.8	41
68	Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 948-954.	0.8	4
69	Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 53-58.	1.7	8
70	Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. <i>Oral Oncology</i> , 2017, 71, 180-183.	1.5	7
71	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 1862-1874.	7.0	107
72	Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). <i>Frontiers in Oncology</i> , 2016, 6, 232.	2.8	82

#	ARTICLE	IF	CITATIONS
73	p16-positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high-risk human papillomavirus or prognosis and implications for the workup of the unknown primary. <i>Cancer</i> , 2016, 122, 1201-1208.	4.1	40
74	BRAF Inhibition in <i>BRAF</i> ^{V600E} -Positive Anaplastic Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 249-254.	4.9	38
75	Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas. <i>Clinical Epigenetics</i> , 2016, 8, 74.	4.1	8
76	Recent Insights and Advances in the Management of Merkel Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 637-646.	2.5	30
77	Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1117-21.	2.0	10
78	PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, E1756-61.	2.0	20
79	Oral cyclophosphamide in recurrent ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e154-60.	1.1	21
80	Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 617-625.	6.4	26
81	Abiraterone in Metastatic Salivary Duct Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 288-290.	4.9	18
82	Merkel Cell Carcinoma: Emerging Biology, Current Approaches, and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e519-e526.	3.8	54
83	Ovarian Growing Teratoma Syndrome With Spuriously Elevated β -Fetoprotein. <i>Journal of Clinical Oncology</i> , 2015, 33, e99-e100.	1.6	8
84	Safety and cost analysis of an 18FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. <i>Oral Oncology</i> , 2015, 51, 529-535.	1.5	19
85	<i>Pneumocystis jirovecii</i> pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. <i>Leukemia and Lymphoma</i> , 2015, 56, 157-162.	1.3	11
86	18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1825-1832.	6.4	21
87	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. <i>Cancer Research</i> , 2015, 75, 4211-4223.	0.9	65
88	Overview of Advances in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3225-3226.	1.6	39
89	Correlation of <i>p16</i> status, hypoxic imaging using [18F]misonidazole positron emission tomography and outcome in patients with locoregionally advanced head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 89-97.	1.8	35
90	Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. <i>Clinical Epigenetics</i> , 2014, 6, 22.	4.1	19

#	ARTICLE	IF	CITATIONS
91	What is the best treatment for patients with human papillomavirusâ€‘positive and â€‘negative oropharyngeal cancer?. Cancer, 2014, 120, 1462-1470.	4.1	58
92	Differential mechanisms of <i>CDKN2A</i> (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. International Journal of Cancer, 2014, 135, 887-895.	5.1	53
93	T4 squamous cell carcinoma of the oral tongue without mandibular involvement: surgery or chemoradiotherapy?. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 117, 163-169.	0.4	17
94	Tonsillar cancer: The Peter MacCallum experience with unilateral and bilateral irradiation. Head and Neck, 2014, 36, 317-322.	2.0	38
95	Suboptimal health literacy in patients with lung cancer or head and neck cancer. Supportive Care in Cancer, 2013, 21, 2237-2245.	2.2	30
96	Frequency of Fibroblast Growth Factor Receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. Oral Oncology, 2013, 49, 576-581.	1.5	30
97	Imaging of hypoxia with ¹⁸ F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 475-481.	1.8	55
98	A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. Oral Oncology, 2013, 49, 468-474.	1.5	28
99	Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i> -Amplified Ovarian Cancer. Clinical Cancer Research, 2013, 19, 5960-5971.	7.0	97
100	Larynx Preservation for Patients With Locally Advanced Laryngeal Cancer. Journal of Clinical Oncology, 2013, 31, 840-844.	1.6	15
101	Developing a Performance Data Suite to Facilitate Lean Improvement in a Chemotherapy Day Unit. Journal of Oncology Practice, 2013, 9, e115-e121.	2.5	18
102	Treatment response in the neck: p16+ versus p16â€‘ oropharyngeal cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 364-372.	1.8	18
103	Elusive Goal of Targeting Tumor Hypoxia for Therapeutic Gain. Journal of Clinical Oncology, 2012, 30, 1741-1743.	1.6	16
104	Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research, 2012, 18, 1798-1807.	7.0	56
105	Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial. Clinical Cancer Research, 2012, 18, 301-307.	7.0	47
106	Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncology, 2012, 48, 698-702.	1.5	10
107	Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02.. Journal of Clinical Oncology, 2012, 30, 5571-5571.	1.6	1
108	Induction chemotherapy in head and neck cancer: closer to an answer?. Lancet Oncology, The, 2011, 12, 113-114.	10.7	5

#	ARTICLE	IF	CITATIONS
109	Larynx preservation with primary non-surgical treatment for locally advanced larynx cancer. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 229-235.	1.8	8
110	Comparison of self-reported smoking status and physician-recorded smoking status among patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Radiotherapy and Oncology, 2011, 98, 143-144.	0.6	2
111	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 2011, 17, 2538-2548.	7.0	217
112	Current Hepatitis B Screening Practices and Clinical Experience of Reactivation in Patients Undergoing Chemotherapy for Solid Tumors: A Nationwide Survey of Medical Oncologists. Journal of Oncology Practice, 2011, 7, 141-147.	2.5	45
113	Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation. Clinical Cancer Research, 2011, 17, 5152-5160.	7.0	49
114	Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors. Journal of Clinical Oncology, 2011, 29, 3270-3277.	1.6	60
115	Prolonged Remission in a Patient With Nasopharyngeal Carcinoma With a Solitary Bone Metastasis. Journal of Clinical Oncology, 2011, 29, e135-e137.	1.6	13
116	Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1230-1237.	2.5	84
117	Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. Journal of Thoracic Oncology, 2010, 5, 1616-1622.	1.1	121
118	Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer. International Journal of Gynecological Cancer, 2010, 20, 827-833.	2.5	27
119	A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 65, 791-801.	2.3	86
120	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology, 2010, 119, 32-37.	1.4	228
121	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology, 2010, 28, 2989-2995.	1.6	339
122	Prognostic Significance of p16 ^{INK4A} and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology, 2010, 28, 4142-4148.	1.6	679
123	Oropharyngeal Cancer, Human Papilloma Virus, and Clinical Trials. Journal of Clinical Oncology, 2010, 28, 1-3.	1.6	78
124	Optimising the therapeutic ratio in head and neck cancer. Lancet Oncology, The, 2010, 11, 287-291.	10.7	59
125	Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. Journal of Clinical Oncology, 2010, 28, 2996-3001.	1.6	683
126	High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 527-533.	1.0	42

#	ARTICLE	IF	CITATIONS
127	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 1864-1871.	1.6	353
128	Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. <i>Head and Neck</i> , 2009, 31, 867-876.	2.0	156
129	The role of PET-CT in the management of patients with advanced cancer of the head and neck. <i>Current Oncology Reports</i> , 2008, 10, 149-155.	4.0	18
130	N2â€”N3 neck nodal control without planned neck dissection for clinical/radiologic complete respondersâ€”Results of Trans Tasman Radiation Oncology Group Study 98.02. <i>Head and Neck</i> , 2008, 30, 737-742.	2.0	109
131	Weekly Carboplatin Reduces Toxicity During Synchronous Chemoradiotherapy for Merkel Cell Carcinoma of Skin. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1070-1074.	0.8	41
132	Sinonasal Malignancies of Neuroendocrine Origin. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1297-1316.	2.2	22
133	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 547-552.	1.4	48
134	Longâ€”term survival following chemoradiation for inoperable nonâ€”small cell lung cancer. <i>Medical Journal of Australia</i> , 2008, 189, 557-559.	1.7	3
135	How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?. <i>Cancer</i> , 2007, 109, 117-124.	4.1	60
136	Hypoxia in Head and Neck Cancer: Studies With Hypoxic Positron Emission Tomography Imaging and Hypoxic Cytotoxins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S61-S63.	0.8	32
137	Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 114-119.	0.8	164
138	Prognostic Significance of [18F]-Misonidazole Positron Emission Tomographyâ€”Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02. <i>Journal of Clinical Oncology</i> , 2006, 24, 2098-2104.	1.6	532
139	Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1384-1391.	6.4	135
140	Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801). <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1389-1396.	1.3	17
141	The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin. <i>Molecular Imaging and Biology</i> , 2005, 7, 236-243.	2.6	23
142	Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). <i>Journal of Clinical Oncology</i> , 2005, 23, 79-87.	1.6	237
143	An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. <i>Cancer Research</i> , 2005, 65, 4031-4040.	0.9	206
144	The â€”QUAD SHOTâ€”a phase II study of palliative radiotherapy for incurable head and neck cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 137-142.	0.6	201

#	ARTICLE	IF	CITATIONS
145	Strategies to overcome accelerated repopulation and hypoxia—what have we learned from clinical trials?. <i>Seminars in Oncology</i> , 2004, 31, 802-808.	2.2	28
146	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 417-421.	1.4	23
147	A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 407-414.	2.3	6
148	Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. <i>Head and Neck</i> , 2004, 26, 435-441.	2.0	108
149	Impact of Positron Emission Tomography on the Management of Patients With Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 164-171.	1.3	86
150	The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. <i>Head and Neck</i> , 2003, 25, 138-145.	2.0	77
151	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2237-2246.	1.6	2,822
152	Promising New Approaches in the Treatment of Advanced Head and Neck Cancer. <i>American Journal of Cancer</i> , 2003, 2, 335-347.	0.4	1
153	High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROC 96:07. <i>Journal of Clinical Oncology</i> , 2003, 21, 4371-4376.	1.6	252
154	Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1285-1292.	1.6	414
155	FDG-PET-Detected Extracranial Metastasis in Patients with Non-Small Cell Lung Cancer Undergoing Staging for Surgery or Radical Radiotherapy. <i>Acta Oncologica</i> , 2003, 42, 48-54.	1.8	40
156	Merkel cell carcinoma — current therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2187-2192.	1.8	5
157	Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. <i>Clinical Cancer Research</i> , 2003, 9, 2040-8.	7.0	31
158	Phase II study of imatinib in patients with small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5880-7.	7.0	145
159	Excellent Disease Control and Survival in Patients With Advanced Nasopharyngeal Cancer Treated With Chemoradiation. <i>Journal of Clinical Oncology</i> , 2002, 20, 1845-1852.	1.6	135
160	Phase II Trial of Continuous Infusion Carboplatin, 5-Fluorouracil, and Radiotherapy for Localized Cancer of the Esophagus. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 277-282.	1.3	9
161	Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition. <i>Journal of Clinical Oncology</i> , 2002, 20, 110-124.	1.6	441
162	The Local-Regionally Advanced Nasopharyngeal Carcinoma Jigsaw Puzzle: Where Does the Chemotherapy Piece Fit?. <i>Journal of Clinical Oncology</i> , 2002, 20, 1968-1970.	1.6	8

#	ARTICLE	IF	CITATIONS
163	Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 535-542.	1.6	183
164	A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. <i>Medical Journal of Australia</i> , 2001, 174, 312-313.	1.7	1
165	F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma. <i>Cancer</i> , 2001, 92, 886-895.	4.1	221
166	Repetitive High-Dose Topotecan, Carboplatin, and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study. <i>Gynecologic Oncology</i> , 2001, 81, 216-224.	1.4	11
167	Radiation with concurrent late chemotherapy intensification (â€chemoboostâ€™™) for locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2000, 54, 123-127.	0.6	54
168	A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. <i>Investigational New Drugs</i> , 1999, 17, 73-80.	2.6	3
169	A Phase II Trial of Carboplatin and Etoposide for Relapsed or Metastatic Carcinoma of the Cervix. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1998, 38, 87-90.	1.0	2
170	Review : Cremophor: Pharmacological activity of an "inert" solubiliser. <i>Journal of Oncology Pharmacy Practice</i> , 1997, 3, 186-192.	0.9	7
171	Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 557-560.	2.3	30
172	Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel. <i>Gynecologic Oncology</i> , 1996, 63, 89-93.	1.4	238
173	Rectal adenocarcinoma with germ cell elements treated with chemotherapy. <i>Pathology</i> , 1993, 25, 243-246.	0.6	20
174	Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy. <i>Cancer</i> , 1991, 68, 1021-1025.	4.1	16